AI / LLMMulti-region
← Sticker Wall
JOURNEY · DETAIL
Yingdong Medical: A Pioneer in Global Cardiovascular AI Imaging, Focused on Compliant Diagnostic Assistance
Founded: Gong Nanjie · Shenzhen Yingdong Medical Technology Co., Ltd.
JOURNEY
Key Fields
FIELD STAMPSIndustryAI / LLM
RegionMulti-region
ScaleMid-size
ChannelOther
Origin
Founder Gong Nanjie, a former imaging algorithm expert at Huawei, observed in 2016 that China faced a shortage of over 300,000 cardiovascular CT radiologists. Simultaneously, the overseas cardiovascular AI diagnostic market lacked direct competitors, and high regulatory barriers offered protection against domestic market saturation. He left his 2 million RMB annual salary at Huawei to start the company, adopting a 'compliance-first' approach to R&D from day one, focusing specifically on cardiovascular AI-assisted diagnostics.
Milestones
2016
Inception Failure
Gong Nanjie founded Yingdong Medical in Shenzhen, initially targeting the domestic chest X-ray lung nodule screening market. Despite investing 5 million RMB in algorithm development, the company struggled as incumbents like Shukun and Infervision already dominated over 80% of the top-tier hospital market. After 8 months, they secured orders from only 2 primary care clinics, generating less than 100,000 RMB in revenue, leaving the team near bankruptcy.
2017
Pivot Turning Point
After a strategic review, the team identified a $12 billion annual demand gap in overseas cardiovascular CT imaging, a segment largely ignored by domestic players focused on the local market. They scrapped the lung nodule product line to go 'all-in' on cardiovascular AI. Aligning with US FDA standards, they developed a Fractional Flow Reserve (FFR) algorithm for cardiovascular CT by year-end, achieving a clinical accuracy of 92%, surpassing the industry average of 85%.
2018
Growth PMF
Secured 15 million RMB in Pre-A funding, investing 12 million RMB into FDA certification. In December, they received FDA Class II medical device clearance, becoming the first Chinese cardiovascular AI imaging firm to do so. They signed a 5-year exclusive distribution agreement with Vizient, a top North American cardiovascular imaging distributor, resulting in over 30 million RMB in overseas revenue and the company's first year of profitability.
2021
Adjustment Pivot
The global pandemic led to widespread budget cuts in overseas hospitals, delaying planned certifications for the EU and Japan. 2021 revenue fell 42% year-on-year, forcing the team to downsize from 120 to 70 employees. Gong Nanjie mortgaged his personal property to raise 8 million RMB to keep operations afloat. The company pivoted its product strategy, expanding from high-end FFR scenarios to routine cardiovascular screening, reducing the procurement threshold from 500,000 RMB per unit to under 100,000 RMB.
2024
Expansion Growth
Successfully obtained EU CE MDR certification and China NMPA Class III medical device certification. Products are now deployed in over 1,200 hospitals across 37 countries. The cardiovascular AI system processes over 50 million cases annually. Annual revenue reached 420 million RMB, with 78% coming from overseas markets and a gross margin of 72%. With a valuation exceeding 3 billion RMB, it has become the world's second-largest cardiovascular AI imaging company by revenue.
Turning Points
- 2017: Scrapped the domestic chest X-ray product line to go all-in on cardiovascular AI imaging.
- 2018: Secured FDA Class II certification, opening the door to the high-end North American medical market.
- 2024: Simultaneously secured core certifications in China, the US, and Europe, enabling large-scale global deployment.
Failures & Pitfalls
- 2016: Entered the domestic chest X-ray market only to be squeezed out by incumbents, securing only 2 orders and less than 100,000 RMB in revenue over 8 months.
- 2021: Pandemic-induced budget cuts in overseas hospitals caused a 42% revenue drop, forcing a 30% staff reduction.
- 2022: Attempted to expand into B2C AI cardiovascular health screening, but was shut down by regulators due to medical compliance issues, resulting in a cumulative loss of 12 million RMB.
关键成功要素
- Adopted the world's highest compliance standards from the start to drive R&D, avoiding domestic market homogenization.
- Prioritized obtaining medical device certifications in core markets (China, US, Europe) to build a regulatory moat.
- Entered via high-end FFR clinical scenarios to establish brand recognition, then expanded into routine screening to lower customer procurement barriers.
- Partnered with top global cardiovascular distributors to build a localized sales network, avoiding the high costs of building an in-house team.
Lessons
- In medical AI, do not blindly follow trends; identify niche segments with genuine clinical gaps and low competition.
- For international expansion, securing regulatory compliance in target markets is mandatory; products without certifications have zero competitiveness abroad.
- Medical AI firms must strictly manage cash flow; financing cycles must align with certification timelines to avoid reckless team expansion.
- For high-end medical products, partnering with global top-tier distributors is over 10 times more efficient than building an internal sales force.
Core Data
- 2024 Annual Revenue：420 million RMB
- Gross Margin：72%
- Overseas Revenue Share：78%
- Global Hospital Deployment：1,200+ hospitals across 37 countries
- Annual Cardiovascular Cases Processed：Over 50 million
- Core Certifications Secured：3 (FDA, CE MDR, NMPA Class III)
- 2024 Valuation：3 billion RMB
Competitors / Peers
Competitors include domestic cardiovascular AI imaging firms like Shukun Technology and Infervision, as well as international players such as HeartFlow and Arterys. Shukun Technology focuses on full-disease imaging coverage, while Infervision is known for respiratory imaging. HeartFlow is a first-mover in the overseas FFR market. Yingdong Medical's core advantage lies in holding simultaneous certifications in China, the US, and Europe, with an FFR algorithm accuracy 7 percentage points above the industry average and a 2024 overseas revenue growth rate of 120%, far exceeding the industry average of 45%.